0001580149 false 0001580149 2021-10-13 2021-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

     
     

FORM 8-K

     
     

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) October 13, 2021

 

BioVie Inc.
(Exact Name of Registrant as Specified in Its Charter)

 

Nevada   000-55292   46-2510769
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (I.R.S. Employer Identification No.)

 

2120 Colorado Avenue, #230
Santa Monica, California
  90404
(Address of Principal Executive Offices)   (Zip Code)
     

(310) 444-4300
(Registrant’s Telephone Number, Including Area Code)

   
   

(Former Name or Former Address, if Changed Since Last Report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Class A Common Stock, par value $0.0001 per share BIVI The NASDAQ Stock Market, LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

-1-

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On October 13, 2021, BioVie Inc., a Nevada corporation (the “Company”) held its 2021 Annual Meeting of stockholders (the “Annual Meeting”). The following matters were considered:

 

1. Election of Directors

 

Stockholders elected all of the Company’s nominees for director for one-year terms expiring on the next annual meeting of stockholders. The voting results were as follows:

 

   For  Withhold  Broker Non-Vote  
(1) TERREN S. PEIZER  20,445,440   391,779   1,865,518  
(2) CUONG DO  20,823,834   13,385   1,865,518  
(3) JIM LANG  20,821,158   16,061   1,865,518  
(4) MICHAEL SHERMAN  20,823,833   13,386   1,865,518  
(5) RICHARD J. BERMAN  20,302,945   534,274   1,865,518  
(6) STEVE GORLIN  20,823,833   13,386   1,865,518  
(7) ROBERT HARIRI, M.D. PHD  20,821,025   16,194   1,865,518  
(8) SIGMUND ROGICH  20,823,833   13,386   1,865,518  

 

2. Approval and Ratification of Auditors

 

Stockholders approved and ratified the appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the 2022 fiscal year. The voting results were as follows:

 

For  Against  Abstain  Broker Non-Vote
22,674,262  26,010  2,465  -0-

 

3. Advisory Say-on-Pay Resolution

 

Stockholders approved the following resolution “RESOLVED” that the stockholders approve the compensation of the Company’s named executive officers as disclosed in the compensation tables and the related disclosure contained in the proxy statement. The voting results were as follows:

 

For  Against  Abstain  Broker Non-Vote
20,780,782  27,943  28,494  1,865,518

 

4. Advisory Resolution on Frequency of Say-on-Pay Resolution

 

Stockholders approved the following resolution “RESOLVED” that the stockholders wish the Company to include an advisory vote on the compensation of the Company’s named executive officers pursuant to Section 14A of the Securities Exchange Act of 1934 every (i) year, (ii) two years, or (iii) three years (select one). The voting results were as follows:

 

Three Years  Two Years  One Year  Abstain  Broker Non-Vote
20,200,510  5,100  596,674  34,935  1,865,518

 

In light of the foregoing vote regarding Proposal Four, the Company has decided to include an advisory stockholder vote on the compensation of executives in its proxy materials every three years.

-2-

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: October 14, 2021

 

  BIOVIE INC.  
       
  By: /s/ Joanne Wendy Kim  
  Name:   Joanne Wendy Kim  
  Title: Chief Financial Officer  

-3-